Skip to content
LATEST
Health

Roche gains FDA path for up to 22 Ionify assays

The De Novo decision adds gabapentin monitoring to Roche’s U.S. mass-spectrometry menu and may speed future assay additions under an FDA-authorized PCCP.

Roche gains FDA path for up to 22 Ionify assays

Roche said in a Nov. 16 investor update that the FDA granted De Novo authorization for its cobas® pro i 601 platform with the Ionify® Gabapentin assay.

The authorization matters because Roche said an FDA-authorized Predetermined Change Control Plan, or PCCP, includes potential expansion of up to 22 Ionify® assays on the same platform as requirements are met.

The cobas® Mass Spec solution is designed to move mass spectrometry, a laboratory method used for highly specific measurement, into more routine clinical settings through an automated workflow.

The first authorized Ionify® Gabapentin assay adds therapeutic drug monitoring to Roche’s U.S. menu. Roche said that menu already includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, including estradiol and 17-Hydroxyprogesterone.

“Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories,” Dan Malarek, president and CEO of Roche Diagnostics North America, said in the investor update. “By automating and standardizing this technology, we’re helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results.”

The FDA’s De Novo pathway is used for certain novel medical devices. Roche said it will use the authorized PCCP to support future clinical mass-spectrometry menu expansion while maintaining safety and quality standards.

The company did not say the additional assays are available now. Roche said they will be introduced in the future as applicable PCCP requirements are met.

Roche said the cobas® Mass Spec solution received the Best New Clinical Diagnostics Instrumentation of 2024 award in the Scientists' Choice Awards® 2025 in July 2025.

Source: company investor update, Roche, Nov. 16, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news